Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 67

1.

Targeting platelet nitric oxide resistance with ramipril: unraveling mechanisms of atherothrombotic risk reduction with angiotensin-converting enzyme inhibitors.

Angiolillo DJ, Capodanno D.

J Am Coll Cardiol. 2012 Sep 4;60(10):895-7. doi: 10.1016/j.jacc.2012.02.046. Epub 2012 Jun 7. No abstract available.

2.

Ramipril sensitizes platelets to nitric oxide: implications for therapy in high-risk patients.

Willoughby SR, Rajendran S, Chan WP, Procter N, Leslie S, Liberts EA, Heresztyn T, Chirkov YY, Horowitz JD.

J Am Coll Cardiol. 2012 Sep 4;60(10):887-94. doi: 10.1016/j.jacc.2012.01.066. Epub 2012 Jun 6.

3.

Reciprocal regulation of NO signaling and TXNIP expression in humans: impact of aging and ramipril therapy.

Sverdlov AL, Chan WP, Procter NE, Chirkov YY, Ngo DT, Horowitz JD.

Int J Cardiol. 2013 Oct 12;168(5):4624-30. doi: 10.1016/j.ijcard.2013.07.159. Epub 2013 Jul 25.

PMID:
23958415
4.

Effect of isatin on nitric oxide-stimulated soluble guanylate cyclase from human platelets.

Medvedev A, Bussygyna O, Pyatakova N, Glover V, Severina I.

Biochem Pharmacol. 2002 Feb 15;63(4):763-6.

PMID:
11992646
5.

Ambroxol as an inhibitor of nitric oxide-dependent activation of soluble guanylate cyclase.

Severina IS, Bussygina OG, Pyatakova NV, Khropov YV, Krasnoperov RA.

Eur J Pharmacol. 2000 Oct 27;407(1-2):61-4.

PMID:
11050291
6.
7.
8.

Ramipril improves oxidative stress-related vascular endothelial dysfunction in db/db mice.

Liang W, Tan CY, Ang L, Sallam N, Granville DJ, Wright JM, Laher I.

J Physiol Sci. 2008 Dec;58(6):405-11. doi: 10.2170/physiolsci.RP012808.

PMID:
18845058
9.

Bradykinin and the therapeutic actions of angiotensin-converting enzyme inhibitors.

Berkenboom G.

Am J Cardiol. 1998 Nov 19;82(10A):11S-13S. Review. No abstract available.

PMID:
9860348
11.

The effects of ramipril on sympathetic nervous system function in older patients with hypertension.

Lee CC, Sidani MA, Hogikyan RV, Supiano MA.

Clin Pharmacol Ther. 1999 Apr;65(4):420-7.

12.

Benzodifuroxan as an NO-dependent activator of soluble guanylate cyclase and a novel highly effective inhibitor of platelet aggregation.

Bussygina OG, Pyatakova NV, Khropov YV, Ovchinnikov IV, Makhova NN, Severina IS.

Biochemistry (Mosc). 2000 Apr;65(4):457-62.

PMID:
10810184
13.

Differential antiplatelet effects of angiotensin converting enzyme inhibitors: comparison of ex vivo platelet aggregation in cardiovascular patients with ramipril, captopril and enalapril.

Skowasch D, Viktor A, Schneider-Schmitt M, Lüderitz B, Nickenig G, Bauriedel G.

Clin Res Cardiol. 2006 Apr;95(4):212-6. Epub 2006 Feb 17.

PMID:
16598590
14.

[The role of thiols in the stimulation of soluble guanylate cyclase by a new class of enzyme activators generating nitric oxide].

Belushkina NN, Riaposova IK, Severina IS.

Biull Eksp Biol Med. 1997 Jan;123(1):39-42. Russian. No abstract available.

PMID:
9213454
16.

Derivatives of benzotetrazine-1,3-dioxide are new NO-donors, activators of soluble guanylate cyclase, and inhibitors of platelet aggregation.

Pyatakova NV, Khropov YV, Churakov AM, Tarasova NI, Serezhenkov VA, Vanin AF, Tartakovsky VA, Severina IS.

Biochemistry (Mosc). 2002 Mar;67(3):329-34.

17.

Ramipril improves nitric oxide availability in hypertensive rats with failing hearts after myocardial infarction.

Linz W, Itter G, Dobrucki LW, Malinski T, Wiemer G.

J Renin Angiotensin Aldosterone Syst. 2003 Sep;4(3):180-5.

PMID:
14608524
18.

Angiotensin converting enzyme inhibitors, left ventricular hypertrophy and fibrosis.

Linz W, Wiemer G, Schaper J, Zimmermann R, Nagasawa K, Gohlke P, Unger T, Schölkens BA.

Mol Cell Biochem. 1995 Jun 7-21;147(1-2):89-97. Review.

PMID:
7494560
19.

Increase in reactivity of human platelet guanylate cyclase during aggregation potentiates the disaggregating capacity of sodium nitroprusside.

Chirkov YY, Belushkina NN, Tyshchuk IA, Severina IS, Horowitz JD.

Clin Exp Pharmacol Physiol. 1991 Jul;18(7):517-24.

PMID:
1680588
20.

Age decreases nitric oxide synthesis and responsiveness in human platelets and increases formation of monocyte-platelet aggregates.

Goubareva I, Gkaliagkousi E, Shah A, Queen L, Ritter J, Ferro A.

Cardiovasc Res. 2007 Sep 1;75(4):793-802. Epub 2007 May 24.

PMID:
17572401

Supplemental Content

Support Center